SANION.ST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:23):

Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark...

Stats
Dzisiejszy wolumen	386 306
Średni wolumen	395 716
Kapitalizacja rynkowa	206.68M
EPS	SEK0 ( 2024-02-28 )
Następna data zysków	( SEK0 ) 2024-05-29
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-1.290
ATR14	SEK0.0130 (0.70%)

Wolumen Korelacja

Długi: 0.16 (neutral)

Krótki: -0.25 (neutral)

Signal:(60.281) Neutral

Saniona AB (publ) Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Saniona AB (publ) Korelacja - Waluta/Towar

-0.04
( neutral )

-0.47
( neutral )

0.00
( neutral )

-0.59
( weak negative )

0.00
( neutral )

0.42
( neutral )

Saniona AB (publ) Finanse

Annual	2023
Przychody:	SEK16.84M
Zysk brutto:	SEK-79.35M (-471.18 %)
EPS:	SEK-1.290

FY	2023
Przychody:	SEK16.84M
Zysk brutto:	SEK-79.35M (-471.18 %)
EPS:	SEK-1.290

FY	2022
Przychody:	SEK15.28M
Zysk brutto:	SEK10.81M (70.72 %)
EPS:	SEK-3.33

FY	2021
Przychody:	SEK10.48M
Zysk brutto:	SEK5.85M (55.81 %)
EPS:	SEK-6.59

Financial Reports:

No articles found.

Saniona AB (publ)

Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.